Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries

M. Balcerek, R. Schilling, J. Byrne, U. Dirksen, H. Cario, MJ. Fernandez-Gonzalez, T. Kepak, E. Korte, J. Kruseova, M. Kunstreich, H. Lackner, T. Langer, M. Sawicka-Zukowska, J. Stefanowicz, G. Strauß, A. Borgmann-Staudt, PanCareLIFE,

. 2020 ; 179 (1) : 51-60. [pub] 20190907

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028638

Grantová podpora
602030 European Union's Seventh Framework Programme for research, technological development and demonstration; PanCareLIFE WP2b
EKPS201607 Berliner Krebsgesellschaft

E-zdroje Online Plný text

NLK ProQuest Central od 1996-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost) od 2012-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1997-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1996-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1996-01-01 do Před 1 rokem

Odkazy

PubMed 31493021
DOI 10.1007/s00431-019-03459-9
Knihovny.cz E-zdroje

Infertility is a relevant late-effect following cancer treatment; yet, a large proportion of survivors cannot recall having been informed of this risk. In an intervention study, we examined if and how supportive patient information material on fertility/fertility-preserving measures influences utilization of cryopreservation in adolescent cancer patients. The control group, recruited 03/2014-01/2016, received the usual patient education at initial diagnosis. The intervention group, recruited 04/2016-10/2017, received patient education supported by a fertility flyer and brochure. Patients and parents were each asked questions on utilization of cryopreservation in a questionnaire 3 and 6 months after initial diagnosis. Patient core and therapy data were obtained from medical records. Overall, cryopreservation rates showed no significant difference between the control (32.7%, n = 37/113) and intervention group (36.6%, n = 37/101). In the control group, cryopreservation was associated with gender (OR 0.100, CI 0.023-0.427), age (OR 1.559, CI 1.077-2.258) and recalling information on fertility protection (OR 33.663, CI 2.100-539.574); in the intervention group, cryopreservation was related to gender (OR 0.093, CI 0.026-0.330) and the estimated infertility risk (OR 43.665, CI 2.157-883.974).Conclusion: Cryopreservation rates did not overall increase following the intervention; however, the individual risk seemed to be brought into attention more: Those at risk, including younger patients, cryopreserved at higher rates.What is Known:•Infertility is a relevant late-effect following adolescent cancer.•Guidelines recommend to offer fertility protection before cancer treatment.•A relevant proportion of adolescents with cancer are not aware of this risk.•Fertility protection seems under-used in cancer patients at risk for infertility.What is New:•Information material on fertility and protection in adolescents did not increase overall rates of cryopreservation.•Cryopreservation rates were improved according to individual risk for infertility.•Our flyers and brochures on fertility in cancer patients are available in various languages.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028638
003      
CZ-PrNML
005      
20210114154532.0
007      
ta
008      
210105s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00431-019-03459-9 $2 doi
035    __
$a (PubMed)31493021
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Balcerek, Magdalena $u Charité - Universitätsmedizin, Berlin, Germany. Berlin Institute of Health (BIH), Berlin, Germany.
245    10
$a Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries / $c M. Balcerek, R. Schilling, J. Byrne, U. Dirksen, H. Cario, MJ. Fernandez-Gonzalez, T. Kepak, E. Korte, J. Kruseova, M. Kunstreich, H. Lackner, T. Langer, M. Sawicka-Zukowska, J. Stefanowicz, G. Strauß, A. Borgmann-Staudt, PanCareLIFE,
520    9_
$a Infertility is a relevant late-effect following cancer treatment; yet, a large proportion of survivors cannot recall having been informed of this risk. In an intervention study, we examined if and how supportive patient information material on fertility/fertility-preserving measures influences utilization of cryopreservation in adolescent cancer patients. The control group, recruited 03/2014-01/2016, received the usual patient education at initial diagnosis. The intervention group, recruited 04/2016-10/2017, received patient education supported by a fertility flyer and brochure. Patients and parents were each asked questions on utilization of cryopreservation in a questionnaire 3 and 6 months after initial diagnosis. Patient core and therapy data were obtained from medical records. Overall, cryopreservation rates showed no significant difference between the control (32.7%, n = 37/113) and intervention group (36.6%, n = 37/101). In the control group, cryopreservation was associated with gender (OR 0.100, CI 0.023-0.427), age (OR 1.559, CI 1.077-2.258) and recalling information on fertility protection (OR 33.663, CI 2.100-539.574); in the intervention group, cryopreservation was related to gender (OR 0.093, CI 0.026-0.330) and the estimated infertility risk (OR 43.665, CI 2.157-883.974).Conclusion: Cryopreservation rates did not overall increase following the intervention; however, the individual risk seemed to be brought into attention more: Those at risk, including younger patients, cryopreserved at higher rates.What is Known:•Infertility is a relevant late-effect following adolescent cancer.•Guidelines recommend to offer fertility protection before cancer treatment.•A relevant proportion of adolescents with cancer are not aware of this risk.•Fertility protection seems under-used in cancer patients at risk for infertility.What is New:•Information material on fertility and protection in adolescents did not increase overall rates of cryopreservation.•Cryopreservation rates were improved according to individual risk for infertility.•Our flyers and brochures on fertility in cancer patients are available in various languages.
650    _2
$a mladiství $7 D000293
650    12
$a kryoprezervace $x statistika a číselné údaje $7 D015925
650    _2
$a ženské pohlaví $7 D005260
650    12
$a zachování plodnosti $x psychologie $x statistika a číselné údaje $7 D059247
650    _2
$a následné studie $7 D005500
650    12
$a zárodečné buňky $7 D005854
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory $x psychologie $x terapie $7 D009369
650    _2
$a hodnocení výsledků zdravotní péče $7 D017063
650    12
$a pacientův souhlas se zdravotní péčí $x psychologie $x statistika a číselné údaje $7 D010342
650    _2
$a vzdělávání pacientů jako téma $x metody $7 D010353
650    _2
$a riziko $7 D012306
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Schilling, Ralph $u Charité - Universitätsmedizin, Berlin, Germany.
700    1_
$a Byrne, Julianne $u Boyne Research Institute, Drogheda, Ireland.
700    1_
$a Dirksen, Uta $u West German Cancer Centre, University Hospital Essen Paediatrics III, Essen, Germany. German Cancer Research Centre (DKTK), Heidelberg, Germany.
700    1_
$a Cario, Holger $u Department of Paediatrics and Adolescent Medicine, University Medical Centre, Ulm, Germany.
700    1_
$a Fernandez-Gonzalez, Marta Julia $u Charité - Universitätsmedizin, Berlin, Germany.
700    1_
$a Kepak, Tomas $u University Hospital, Brno, Czech Republic.
700    1_
$a Korte, Elisabeth $u Charité - Universitätsmedizin, Berlin, Germany.
700    1_
$a Kruseova, Jarmila $u Motol Teaching Hospital, Prague, Czech Republic.
700    1_
$a Kunstreich, Marina $u Department of Paediatric Oncology, Haematology and Immunology, Medical Faculty, Heinrich-Heine, University of, Düsseldorf, Germany.
700    1_
$a Lackner, Herwig $u Medical University of Graz, Graz, Austria.
700    1_
$a Langer, Thorsten $u Lübeck Universitätklinik, Lübeck, Germany.
700    1_
$a Sawicka-Zukowska, Malgorzata $u Uniwersytet Medyczny w Białymstoku, Białystok, Poland.
700    1_
$a Stefanowicz, Joanna $u Klinika Pediatrii, Hematologii I Onkologii Gdanski Uniwersytet, Gdansk, Poland.
700    1_
$a Strauß, Gabriele $u Helios Kliniken Berlin-Buch, Klinik für Kinder- und Jungendmedizin, Berlin, Germany.
700    1_
$a Borgmann-Staudt, Anja $u Charité - Universitätsmedizin, Berlin, Germany. anja.borgmann@charite.de.
710    2_
$a PanCareLIFE
773    0_
$w MED00009638 $t European journal of pediatrics $x 1432-1076 $g Roč. 179, č. 1 (2020), s. 51-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31493021 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154528 $b ABA008
999    __
$a ok $b bmc $g 1608973 $s 1119818
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 179 $c 1 $d 51-60 $e 20190907 $i 1432-1076 $m European journal of pediatrics $n Eur J Pediatr $x MED00009638
GRA    __
$a 602030 $p European Union's Seventh Framework Programme for research, technological development and demonstration; PanCareLIFE WP2b
GRA    __
$a EKPS201607 $p Berliner Krebsgesellschaft
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace